88 related articles for article (PubMed ID: 4039797)
1. Ototoxicity of cis-diamminedichloroplatinum.
Vodvárka P; Foukalová J; Mrázek J; Philippová J
Neoplasma; 1985; 32(2):229-38. PubMed ID: 4039797
[TBL] [Abstract][Full Text] [Related]
2. A review of cis-platinum ototoxicity.
Moroso MJ; Blair RL
J Otolaryngol; 1983 Dec; 12(6):365-9. PubMed ID: 6686617
[TBL] [Abstract][Full Text] [Related]
3. [Ototoxic side effects in patients with ovarian cancer treated with cisplatin].
Behling H; Spieske C; Krafft W
Zentralbl Gynakol; 1988; 110(5):277-82. PubMed ID: 3376611
[TBL] [Abstract][Full Text] [Related]
4. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
5. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.
Reddel RR; Kefford RF; Grant JM; Coates AS; Fox RM; Tattersall MH
Cancer Treat Rep; 1982 Jan; 66(1):19-23. PubMed ID: 7198012
[TBL] [Abstract][Full Text] [Related]
6. Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity.
Wallach PM; Love SR; Fiorica JV; Hoffman MS; Flannery MT
J Fla Med Assoc; 1992 Dec; 79(12):821-2. PubMed ID: 1474367
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
8. Analysis of hearing loss due to cis-diamminedichloroplatinum-II.
van Zeijl LG; Conijn EA; Rodenburg M; Tange RA; Brocaar MP
Arch Otorhinolaryngol; 1984; 239(3):255-62. PubMed ID: 6539589
[TBL] [Abstract][Full Text] [Related]
9. [Cisplatin ototoxicity. A clinical study].
Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
[TBL] [Abstract][Full Text] [Related]
10. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
11. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
12. [Fundamental studies on intravesical instillation of cis-diamminedichloroplatinum for treatment of urinary bladder tumors. II. On the effects of intravesical instillation of cis-diamminedichloroplatinum in bladder cancer patients].
Hirao Y; Iwai A; Moriya A; Matsuki H; Yoshida Y; Komada S; Sasaki K; Kubota K; Sanma S; Babaya K
Hinyokika Kiyo; 1985 Sep; 31(9):1565-73. PubMed ID: 4083214
[TBL] [Abstract][Full Text] [Related]
13. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
14. [The ototoxicity of cisplatin: a clinical study].
Vantrappen G; Rector E; Debruyne F
Acta Otorhinolaryngol Belg; 1990; 44(4):415-21. PubMed ID: 2093285
[TBL] [Abstract][Full Text] [Related]
15. [Experiences with cisplatin (Platidiam) chemotherapy in secondary resistant ovarian carcinomas].
Krafft W; Mechl Z; Behling H; Brückmann D; Preibsch W; Kademann J; Schirmer A
Zentralbl Gynakol; 1984; 106(3):175-83. PubMed ID: 6538371
[TBL] [Abstract][Full Text] [Related]
16. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study.
Low WK; Toh ST; Wee J; Fook-Chong SM; Wang DY
J Clin Oncol; 2006 Apr; 24(12):1904-9. PubMed ID: 16622266
[TBL] [Abstract][Full Text] [Related]
17. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.
Waters GS; Ahmad M; Katsarkas A; Stanimir G; McKay J
Ear Hear; 1991 Apr; 12(2):91-102. PubMed ID: 2065844
[TBL] [Abstract][Full Text] [Related]
18. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.
Kurihara N; Kubota T; Hoshiya Y; Otani Y; Ando N; Kumai K; Kitajima M
J Surg Oncol; 1996 Jun; 62(2):135-8. PubMed ID: 8649040
[TBL] [Abstract][Full Text] [Related]
20. cis-diamminedichloroplatinum(II) nephrotoxicity: tubular function after rescue with sodium diethyldithiocarbamate in rats.
Elliott WC; Newcom SR; Houghton DC; Baines-Hunter J; Bennett WM
Cancer Res; 1983 Aug; 43(8):3759-62. PubMed ID: 6305493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
